Patients with certain GLP1R variants may respond optimally to semaglutide, while those with favorable GIPR profiles often excel on tirzepatide
The FDA's April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B bulks list is a real development with a real public comment deadline of June 29, 2026
Long-term heavy metal exposure can lead to physical, muscular and neurological degenerative changes in the brain that set the stage for not only Alzheimers disease, but also dementia, Parkinsons disease and multiple sclerosis
Glutathione and Pregnancy: The Safety Consideration A common question among expectant mothers is, "Can I take glutathione during pregnancy?" Understanding the safety of glutathione supplementation is paramount
Key Background Researchers have studied the possible risks associated with Ozempic, Wegovy and other similar drugs as theyve increased in popularity